Sino Biopharmaceutical Limited has announced that its clinical trial application for TQF3250, an orally administered, biased GLP-1 receptor agonist intended for weight loss, has been approved by both the China National Medical Products Administration (NMPA) and the United States Food and Drug Administration (FDA). The approval allows the company to proceed with clinical trials of TQF3250, which is also being developed for the treatment of Type 2 diabetes. No other organizations are mentioned as recipients of this regulatory approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251204-11944326), on December 04, 2025, and is solely responsible for the information contained therein.